AARD
Aardvark Therapeutics, Inc. Common Stock NASDAQ Listed Feb 13, 2025$4.79
-5.34%
vs $5.06
Mkt Cap $94.0M
52w Low $3.48
9.4% of range
52w High $17.41
50d MA $4.73
200d MA $9.38
P/E (TTM)
—
EV/EBITDA
—
P/B
0.9x
Debt/Equity
0.0x
ROE
-54.0%
P/FCF
-1.7x
RSI (14)
73.00
ATR (14)
$0.40
Beta
5.34
50d MA
$4.73
200d MA
$9.38
Avg Volume
225.5K
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
4370 La Jolla Village Drive · San Diego, CA 92122 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 23, 2026 | AMC | -0.83 | -0.81 | +2.1% | 4.07 | -1.7% | -7.4% | -6.1% | -0.8% | +1.1% | +2.5% | — |
| Nov 13, 2025 | AMC | -0.80 | -0.75 | +6.1% | 10.86 | -4.6% | -8.7% | +4.4% | -5.0% | +6.3% | -9.8% | — |
| Aug 13, 2025 | AMC | -0.60 | -0.66 | -10.0% | 11.20 | -3.6% | +0.5% | -4.3% | -3.2% | -2.6% | -4.9% | — |
| May 14, 2025 | AMC | -0.67 | -0.71 | -5.5% | 8.74 | +20.7% | +4.0% | +8.8% | +5.5% | +5.5% | +1.1% | — |
| Feb 26, 2025 | AMC | -0.41 | -0.68 | -65.9% | 13.11 | -1.9% | +2.2% | -5.0% | +0.0% | -5.7% | -5.2% | — |
| Sep 30, 2024 | AMC | — | -0.32 | — | — | — | — | — | — | — | — | — |
| Jun 30, 2024 | AMC | — | -2.13 | — | — | — | — | — | — | — | — | — |
| Mar 31, 2024 | AMC | — | -0.17 | — | — | — | — | — | — | — | — | — |
| Dec 31, 2023 | AMC | — | -0.21 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | -0.22 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 15 | Morgan Stanley | Downgrade | Equal-Weight → Underweight | $3 | $6.73 | $4.39 | -34.8% | -32.1% | -4.6% | +0.2% | -1.8% | +5.1% |
| Mar 24 | BTIG | Maintains | Buy → Buy | — | $4.07 | $4.00 | -1.7% | -7.4% | -6.1% | -0.8% | +1.1% | +2.5% |
| Mar 2 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $12.49 | $5.98 | -52.1% | -56.2% | -10.4% | +15.1% | +1.8% | +1.9% |
| Mar 2 | Stifel | Downgrade | Buy → Hold | — | $12.49 | $5.98 | -52.1% | -56.2% | -10.4% | +15.1% | +1.8% | +1.9% |
| Mar 2 | RBC Capital | Downgrade | Outperform → Sector Perform | — | $12.49 | $5.98 | -52.1% | -56.2% | -10.4% | +15.1% | +1.8% | +1.9% |
| Mar 2 | Oppenheimer | Maintains | Outperform → Outperform | — | $12.49 | $5.98 | -52.1% | -56.2% | -10.4% | +15.1% | +1.8% | +1.9% |
| Mar 2 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $12.49 | $5.98 | -52.1% | -56.2% | -10.4% | +15.1% | +1.8% | +1.9% |
| Mar 2 | BTIG | Maintains | Buy → Buy | — | $12.49 | $5.98 | -52.1% | -56.2% | -10.4% | +15.1% | +1.8% | +1.9% |
| Feb 10 | BTIG | Maintains | Buy → Buy | — | $13.48 | $13.46 | -0.1% | -6.5% | +0.5% | -3.1% | -1.5% | +2.9% |
| Feb 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.65 | $12.65 | +0.0% | +6.6% | -6.5% | +0.5% | -3.1% | -1.5% |
| Nov 14 | RBC Capital | Maintains | Outperform → Outperform | — | $10.86 | $10.36 | -4.6% | -8.7% | +4.4% | -5.0% | +6.3% | -9.8% |
| Sep 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.23 | $11.40 | +1.5% | +1.9% | +6.4% | +4.1% | +4.4% | +3.4% |
| Aug 28 | BofA Securities | Maintains | Buy → Buy | — | $8.99 | $9.18 | +2.1% | -5.6% | -2.2% | +6.7% | -7.7% | +3.8% |
| Aug 14 | RBC Capital | Maintains | Outperform → Outperform | — | $11.20 | $10.80 | -3.6% | +0.5% | -4.3% | -3.2% | -2.6% | -4.9% |
| May 15 | RBC Capital | Maintains | Outperform → Outperform | — | $8.74 | $10.55 | +20.7% | +4.0% | +8.8% | +5.5% | +5.5% | +1.1% |
| Apr 1 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $7.51 | $7.50 | -0.1% | +10.4% | +12.8% | -7.1% | -6.1% | -2.7% |
| Apr 1 | RBC Capital | Maintains | Outperform → Outperform | — | $7.51 | $7.50 | -0.1% | +10.4% | +12.8% | -7.1% | -6.1% | -2.7% |
| Mar 27 | BofA Securities | Maintains | Buy → Buy | — | $9.42 | $10.28 | +9.1% | -5.5% | -13.0% | -3.0% | +10.4% | +12.8% |
No insider trades available.
8-K · 2.02
!! High
Aardvark Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Aardvark Therapeutics reported Q1 2026 financial results and business updates via press release, providing investors with current operational performance and forward guidance.
May 7
8-K · 1.01
!! High
Unknown — 8-K 1.01: Distribution Agreement
AARD's new distribution agreement with Piper Sandler expands market access and sales capabilities, potentially boosting revenue growth and stock valuation through enhanced distribution reach.
Mar 24
8-K
Unknown — 8-K Filing
Aardvark's clinical-stage biotech faces potential FDA concerns requiring urgent dialogue, creating significant execution risk and uncertainty around its metabolic disease pipeline advancement timing.
Mar 23
8-K · 8.01
!! High
Aardvark Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Without access to the actual press release content in Exhibit 99.1, I cannot provide specific details about what Aardvark Therapeutics announced and its investor impact.
Feb 27
8-K · 5.02
!!! Very High
Aardvark Therapeutics, Inc. -- 8-K 5.02: Executive Change
Bryan Jones resigned from Aardvark Therapeutics' board effective February 9, 2026, reducing the company's directorate by one member.
Feb 12
8-K · 8.01
!! High
Aardvark Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Aardvark Therapeutics expanded its Phase 3 HERO trial eligibility to younger children (ages 7+), potentially broadening the treatment population and accelerating enrollment for its developmental therapy.
Feb 10
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Decheng Capital Llc | 3,917,299 | $15M | — | Mar 2026 |
| 2 | Laurion Capital Management Lp | 1,014,911 | $13M | Reduced | Dec 2025 |
| 3 | Citadel Advisors Llc | 1,242,777 | $5M | Reduced | Mar 2026 |
| 4 | Silverarc Capital Management, Llc | 303,939 | $4M | Reduced | Dec 2025 |
| 5 | Vanguard Capital Management Llc | 554,101 | $2M | New | Mar 2026 |
| 6 | Morgan Stanley | 155,908 | $2M | Added | Dec 2025 |
| 7 | Cresset Asset Management, Llc | 141,783 | $2M | New | Sep 2025 |
| 8 | Cantor Fitzgerald, L. P. | 91,682 | $1M | New | Dec 2025 |
| 9 | Two Sigma Investments, Lp | 163,355 | $616K | Added | Mar 2026 |
| 10 | Ubs Group Ag | 157,888 | $595K | Added | Mar 2026 |
| 11 | Aqr Capital Management Llc | 134,495 | $507K | New | Mar 2026 |
| 12 | Millennium Management | 98,334 | $371K | Reduced | Mar 2026 |
| 13 | Northern Trust Corp | 88,599 | $334K | Reduced | Mar 2026 |
| 14 | Vanguard Portfolio Management Llc | 75,149 | $283K | New | Mar 2026 |
| 15 | Woodline Partners Lp | 72,429 | $273K | New | Mar 2026 |
| 16 | Renaissance Technologies Llc | 70,792 | $267K | New | Mar 2026 |
| 17 | Prelude Capital Management, Llc | 30,637 | $116K | New | Mar 2026 |
| 18 | Bank Of New York Mellon Corp | 29,320 | $111K | Added | Mar 2026 |
| 19 | Centiva Capital, Lp | 24,782 | $93K | Reduced | Mar 2026 |
| 20 | Ieq Capital, Llc | 16,485 | $62K | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$94.0M
Enterprise Value
-$16.0M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.05x
P/B
0.88x
P/S
—
P/FCF
-1.73x
EV/EBITDA
—
Shares Out
19.6M
Financials (TTM)
Revenue
$0
Net Income
-$69.9M
EBITDA
-$69.8M
Free Cash Flow
-$54.3M
Op Cash Flow
-$54.2M
EPS Basic
$-2.93
EPS Diluted
$-3.21
EPS Forward
$-3.42
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$117.2M
Total Liab.
$10.5M
Total Equity
$106.6M
Cash
$110.0M
LT Debt
$0
Book Value/Sh
$5.43
Debt/Equity
0.00x
Current Ratio
10.61
Quick Ratio
10.61
Returns & Growth
ROE
-54.0%
ROA
-49.1%
ROIC
-58.6%
Rev Growth YoY
+0.0%
EPS Growth YoY
-84.3%
Price Returns
2W
-38.9%
1M
-24.3%
3M
-67.1%
6M
-58.8%
12M
-60.6%
Technicals
52W High
$17.41
52W Low
$3.48
50d MA
$4.73
200d MA
$9.38
RSI (14)
73.00
ATR (14)
$0.40
Beta
5.34
Avg Volume
225K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$29.33
High
$47.00
Low
$6.00
Median
$35.00
Data updated apr 24, 2026 10:08am
· Source: financialmodelingprep.com